Upcoming Events & Webinars
Join our events and webinars to meet experts, build collaborations and be the first to see new product releases.
Upcoming Webinars
-
2024-03-28T17:00:00Z
What are the advantages of dPCR compared to qPCR? Can I multiplex with digital PCR? How can I improve the LOD of my digital PCR assay? How can I use digital PCR to detect eDNA? How can I quantify viral load in samples with high background noise? How do I check the integrity of my molecules using digital PCR?
And the list of interesting digital PCR questions goes on and on and on. And here's another one: How do I find the answers?
Gain exclusive access to Dr. Jan Rohde, the head digital PCR expert in our support team, and find out more about topics that have left you scratching your head. This is more than a chance to find detailed digital PCR information. The Q&A session is also an opportunity to:
- Access up-to-date digital PCR information
- Gain inspiration from how others are using digital PCR
- Solve problems before they arise by learning from the experience of your colleagues
- Be part of a digital PCR community
- Discover future directions of the technology
Jan Rohde, Senior Technical Sales Manager dPCR
-
2024-04-04T05:00:00Z
As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insights (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.
In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:
- Navigate from VCF to final report with speed, precision, and confidence;
- Easily issue report addendums without the need for re-running a VCF;
- Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
- Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.
Umadevi Thirumurthi, PhD, Associate Director of Global Product Management, Somatic Oncology -
2024-04-04T07:30:00Z
As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insights (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.
In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:
- Navigate from VCF to final report with speed, precision, and confidence;
- Easily issue report addendums without the need for re-running a VCF;
- Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
- Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.
Umadevi Thirumurthi, PhD, Associate Director of Global Product Management, Somatic Oncology -
2024-04-04T11:00:00Z
As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insights (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.
In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:
- Navigate from VCF to final report with speed, precision, and confidence;
- Easily issue report addendums without the need for re-running a VCF;
- Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
- Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.
Umadevi Thirumurthi, PhD, Associate Director of Global Product Management, Somatic Oncology -
2024-04-04T17:00:00Z
As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insights (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.
In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:
- Navigate from VCF to final report with speed, precision, and confidence;
- Easily issue report addendums without the need for re-running a VCF;
- Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
- Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.
Umadevi Thirumurthi, PhD, Associate Director of Global Product Management, Somatic Oncology
-
2024-04-25T05:00:00Z
Discovering new genes implicated in hereditary diseases or cancer progression is challenging yet advancing rapidly due to the increase in next-generation sequencing (NGS) cohort data. These data analyses produce insights into associations between gene variants and diseases and the biological mechanisms of these gene variants.
By combining QIAGEN CLC Genomics Workb-ench, QCII-T and QIAGEN IPA, you can analyze sequencing data obtained from a variety of NGS technologies, annotate gene variants using the world’s most comprehensive and up-to-date curated scientific evidence and find biological connections in gene variants with manually curated scientific findings. Using a streamlined NGS analysis workflow, you’ll get valuable and reliable insights for your research project and speed up your discoveries.
In this training, you’ll:
- Learn to import whole genome or exosome sequencing data into QIAGEN CLC Genomics Workbench and use the ultra-fast LightSpeed Module that delivers an end-to-end NGS FASTQ to VCF pipeline
- Explore the capabilities in QCII-T which can help accelerate your discoveries from hereditary or tumor cohort analyses to find associations between gene variants and diseases
- Learn how to use QIAGEN IPA and its manually curated content, among other integrated scientific evidence, to uncover novel biological mechanisms underlying these gene variants
Tim Hou, PhD, Field Application Scientist -
2024-04-25T07:30:00Z
Discovering new genes implicated in hereditary diseases or cancer progression is challenging yet advancing rapidly due to the increase in next-generation sequencing (NGS) cohort data. These data analyses produce insights into associations between gene variants and diseases and the biological mechanisms of these gene variants.
By combining QIAGEN CLC Genomics Workb-ench, QCII-T and QIAGEN IPA, you can analyze sequencing data obtained from a variety of NGS technologies, annotate gene variants using the world’s most comprehensive and up-to-date curated scientific evidence and find biological connections in gene variants with manually curated scientific findings. Using a streamlined NGS analysis workflow, you’ll get valuable and reliable insights for your research project and speed up your discoveries.
In this training, you’ll:
- Learn to import whole genome or exosome sequencing data into QIAGEN CLC Genomics Workbench and use the ultra-fast LightSpeed Module that delivers an end-to-end NGS FASTQ to VCF pipeline
- Explore the capabilities in QCII-T which can help accelerate your discoveries from hereditary or tumor cohort analyses to find associations between gene variants and diseases
- Learn how to use QIAGEN IPA and its manually curated content, among other integrated scientific evidence, to uncover novel biological mechanisms underlying these gene variants
Tim Hou, PhD, Field Application Scientist -
2024-04-25T11:00:00Z
Discovering new genes implicated in hereditary diseases or cancer progression is challenging yet advancing rapidly due to the increase in next-generation sequencing (NGS) cohort data. These data analyses produce insights into associations between gene variants and diseases and the biological mechanisms of these gene variants.
By combining QIAGEN CLC Genomics Workb-ench, QCII-T and QIAGEN IPA, you can analyze sequencing data obtained from a variety of NGS technologies, annotate gene variants using the world’s most comprehensive and up-to-date curated scientific evidence and find biological connections in gene variants with manually curated scientific findings. Using a streamlined NGS analysis workflow, you’ll get valuable and reliable insights for your research project and speed up your discoveries.
In this training, you’ll:
- Learn to import whole genome or exosome sequencing data into QIAGEN CLC Genomics Workbench and use the ultra-fast LightSpeed Module that delivers an end-to-end NGS FASTQ to VCF pipeline
- Explore the capabilities in QCII-T which can help accelerate your discoveries from hereditary or tumor cohort analyses to find associations between gene variants and diseases
- Learn how to use QIAGEN IPA and its manually curated content, among other integrated scientific evidence, to uncover novel biological mechanisms underlying these gene variants
Tim Hou, PhD, Field Application Scientist -
2024-04-25T11:00:00Z
Discovering new genes implicated in hereditary diseases or cancer progression is challenging yet advancing rapidly due to the increase in next-generation sequencing (NGS) cohort data. These data analyses produce insights into associations between gene variants and diseases and the biological mechanisms of these gene variants.
By combining QIAGEN CLC Genomics Workb-ench, QCII-T and QIAGEN IPA, you can analyze sequencing data obtained from a variety of NGS technologies, annotate gene variants using the world’s most comprehensive and up-to-date curated scientific evidence and find biological connections in gene variants with manually curated scientific findings. Using a streamlined NGS analysis workflow, you’ll get valuable and reliable insights for your research project and speed up your discoveries.
In this training, you’ll:
- Learn to import whole genome or exosome sequencing data into QIAGEN CLC Genomics Workbench and use the ultra-fast LightSpeed Module that delivers an end-to-end NGS FASTQ to VCF pipeline
- Explore the capabilities in QCII-T which can help accelerate your discoveries from hereditary or tumor cohort analyses to find associations between gene variants and diseases
- Learn how to use QIAGEN IPA and its manually curated content, among other integrated scientific evidence, to uncover novel biological mechanisms underlying these gene variants
Tim Hou, PhD, Field Application Scientist